Telix Pharmaceuticals Limited
TLPPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.37B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.37 Billion |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.03 |
| Beta | 0.6 |
| Outstanding Shares | 339,220,212 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 114.69 |
|---|---|
| PEG | -6.88 |
| Price to Sales | 1.26 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$0.04
Consensus analyst estimateRevenue Estimate
$479.63 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 19, 2027
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
$493.82 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Telix Pharmaceuticals Limited
1,184 employees
CEO: Christian Behrenbruch
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medi...